227 related articles for article (PubMed ID: 34605696)
21. A phase II study of postoperative concurrent carboplatin and paclitaxel combined with intensity-modulated pelvic radiotherapy followed by consolidation chemotherapy in surgically treated cervical cancer patients with positive pelvic lymph nodes.
Mabuchi S; Isohashi F; Yokoi T; Takemura M; Yoshino K; Shiki Y; Ito K; Enomoto T; Ogawa K; Kimura T
Gynecol Oncol; 2016 May; 141(2):240-246. PubMed ID: 26883141
[TBL] [Abstract][Full Text] [Related]
22. A Multi-Institutional Retrospective Analysis of Oncologic Outcomes for Patients With Locally Advanced Cervical Cancer Undergoing Platinum-Based Adjuvant Chemotherapy After Concurrent Chemoradiotherapy.
Wu N; Su X; Song H; Li Y; Gu F; Sun X; Li X; Cheng G
Cancer Control; 2021; 28():1073274821989307. PubMed ID: 33593091
[TBL] [Abstract][Full Text] [Related]
23. Prognostic value of post-radiation serum squamous cell carcinoma antigen and primary tumor regression for cervical squamous cell carcinoma.
Wan Q; Yan W; Liu Y; Lin Y; Lu Z
Cancer Biomark; 2020; 29(3):327-335. PubMed ID: 32716344
[TBL] [Abstract][Full Text] [Related]
24. Clinical behaviors and outcomes for adenocarcinoma or adenosquamous carcinoma of cervix treated by radical hysterectomy and adjuvant radiotherapy or chemoradiotherapy.
Huang YT; Wang CC; Tsai CS; Lai CH; Chang TC; Chou HH; Lee SP; Hong JH
Int J Radiat Oncol Biol Phys; 2012 Oct; 84(2):420-7. PubMed ID: 22365621
[TBL] [Abstract][Full Text] [Related]
25. Elevated circulating tumor cells and squamous cell carcinoma antigen levels predict poor survival for patients with locally advanced cervical cancer treated with radiotherapy.
Wen YF; Cheng TT; Chen XL; Huang WJ; Peng HH; Zhou TC; Lin XD; Zeng LS
PLoS One; 2018; 13(10):e0204334. PubMed ID: 30303986
[TBL] [Abstract][Full Text] [Related]
26. The role of squamous cell carcinoma antigen (SCC Ag) in outcome prediction after concurrent chemoradiotherapy and treatment decisions for patients with cervical cancer.
Fu J; Wang W; Wang Y; Liu C; Wang P
Radiat Oncol; 2019 Aug; 14(1):146. PubMed ID: 31416463
[TBL] [Abstract][Full Text] [Related]
27. The clinical values of squamous cell carcinoma antigen and carcinoembryonic antigen in patients with cervical cancer treated with concurrent chemoradiotherapy.
Yoon SM; Shin KH; Kim JY; Seo SS; Park SY; Kang S; Cho KH
Int J Gynecol Cancer; 2007; 17(4):872-8. PubMed ID: 17343571
[TBL] [Abstract][Full Text] [Related]
28. Average log change rate of pretreatment squamous cell carcinoma antigen after concurrent chemoradiotherapy in stage IIIC1 cervical squamous cell carcinoma.
Cho O; Chun M; Chang SJ
Sci Rep; 2024 Apr; 14(1):8710. PubMed ID: 38622276
[TBL] [Abstract][Full Text] [Related]
29. [Significance and implication on changes of serum squamous cell carcinoma antigen in the diagnosis of recurrence squamous cell carcinoma of cervix].
Li Q; Liu S; Liu H; Zhang J; Guo S; Wang L
Zhonghua Fu Chan Ke Za Zhi; 2015 Feb; 50(2):131-6. PubMed ID: 25877611
[TBL] [Abstract][Full Text] [Related]
30. Predictive value of preoperative serum squamous cell carcinoma antigen (SCC-Ag) level on tumor recurrence in cervical squamous cell carcinoma patients treated with radical surgery: A single-institution study.
Guo Q; Zhu J; Wu Y; Wen H; Xia L; Wu X; Ju X
Eur J Surg Oncol; 2020 Jan; 46(1):131-138. PubMed ID: 31481274
[TBL] [Abstract][Full Text] [Related]
31. Definite chemoradiotherapy is a competent treatment option in FIGO stage IB2 cervical cancer compared with radical surgery +/- neoadjuvant chemotherapy.
Hsieh HY; Huang JW; Lu CH; Lin JC; Wang L
J Formos Med Assoc; 2019 Jan; 118(1 Pt 1):99-108. PubMed ID: 29429800
[TBL] [Abstract][Full Text] [Related]
32. Use of serum squamous cell carcinoma antigen for follow-up monitoring of cervical cancer patients who were treated by concurrent chemoradiotherapy.
Yoon SM; Shin KH; Kim JY; Seo SS; Park SY; Moon SH; Cho KH
Radiat Oncol; 2010 Sep; 5():78. PubMed ID: 20840788
[TBL] [Abstract][Full Text] [Related]
33. Neoadjuvant chemotherapy plus intensity-modulated radiotherapy versus concurrent chemoradiotherapy plus adjuvant chemotherapy for the treatment of locoregionally advanced nasopharyngeal carcinoma: a retrospective controlled study.
Qiu WZ; Huang PY; Shi JL; Xia HQ; Zhao C; Cao KJ
Chin J Cancer; 2016 Jan; 35():2. PubMed ID: 26739148
[TBL] [Abstract][Full Text] [Related]
34. Association of pretreatment SUV
Shou H; Yasuo Y; Yuan S; Lou H; Ni J
Int J Gynaecol Obstet; 2021 Jan; 152(1):112-117. PubMed ID: 33141954
[TBL] [Abstract][Full Text] [Related]
35. Extended-field intensity-modulated radiotherapy and concurrent cisplatin-based chemotherapy for postoperative cervical cancer with common iliac or para-aortic lymph node metastases: a retrospective review in a single institution.
Zhang G; Fu C; Zhang Y; Wang J; Qiao N; Yang Q; Cheng Y
Int J Gynecol Cancer; 2012 Sep; 22(7):1220-5. PubMed ID: 22854654
[TBL] [Abstract][Full Text] [Related]
36. The predictive value of measurement of SUVmax and SCC-antigen in patients with pretreatment of primary squamous cell carcinoma of cervix.
Nakamura K; Okumura Y; Kodama J; Hongo A; Kanazawa S; Hiramatsu Y
Gynecol Oncol; 2010 Oct; 119(1):81-6. PubMed ID: 20580064
[TBL] [Abstract][Full Text] [Related]
37. The Validity of Using Human Squamous Cell Carcinoma Associated Antigen and Cytokeratin 19 Fragment Antigen 21-1 to Predict Postoperative Adjuvant Radiotherapy for Nonbulky Early-Stage Squamous Cell Carcinoma of the Cervix.
Liu CZ; Zeng HX; Zhao JJ; Rong Y; Mo ZL; Li LA; Zhang JQ
Int J Gynecol Cancer; 2017 Jun; 27(5):994-1000. PubMed ID: 28498239
[TBL] [Abstract][Full Text] [Related]
38. Postreatment squamous cell carcinoma antigen as a survival prognostic factor in patients with locally advanced cervical cancer. A Spanish multicenter study. The SEGO Spain-GOG group.
Benito V; Lubrano A; Pérez-Regadera JF; Torné A; Gil-Moreno A; Tejerizo-Garcia Á; Vergés R; Díaz-Feijoo B;
Gynecol Oncol; 2021 Aug; 162(2):407-412. PubMed ID: 34119366
[TBL] [Abstract][Full Text] [Related]
39. Clinical implications of elevated pretreatment carcinoembryonic antigen in patients with advanced squamous cell carcinoma of the uterine cervix.
Chen SW; Liang JA; Hung YC; Yeh LS; Chang WC; Yang SN; Lin FJ
Tumour Biol; 2008; 29(4):255-61. PubMed ID: 18781097
[TBL] [Abstract][Full Text] [Related]
40. Preoperative serum squamous cell carcinoma antigen levels in clinical decision making for patients with early-stage cervical cancer.
Reesink-Peters N; van der Velden J; Ten Hoor KA; Boezen HM; de Vries EG; Schilthuis MS; Mourits MJ; Nijman HW; Aalders JG; Hollema H; Pras E; Duk JM; van der Zee AG
J Clin Oncol; 2005 Mar; 23(7):1455-62. PubMed ID: 15735121
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
